Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in pediatric moderate to severe Crohn's disease
2021-005019-30Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ozanimod in Crohn's disease (2 arms), sponsored by Celgene Corporation. Primary endpoint: Clinical remission at Week 64. Started Sep 2022; status: active.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2021-005019-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005019-30.